Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1798 |
Name | pancreatic endocrine carcinoma |
Definition | An islet cell tumor that has_material_basis_in epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer islet cell tumor pancreatic endocrine carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF K601E | Trametinib | pancreatic endocrine carcinoma | predicted - resistant | detail... |
BRAF K601E | Dabrafenib + Trametinib | pancreatic endocrine carcinoma | predicted - resistant | detail... |
BRAF V600E | Vemurafenib | pancreatic endocrine carcinoma | predicted - sensitive | detail... |
VHL inact mut | Belzutifan | pancreatic endocrine carcinoma | sensitive | detail... |
BRAF V600E | Cobimetinib + Vemurafenib | pancreatic endocrine carcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | pancreatic endocrine carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01466036 | Phase II | Cabozantinib | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | Completed | USA | 0 |
NCT02077933 | Phase I | Alpelisib + Everolimus Alpelisib + Everolimus + Exemestane | Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | Completed | USA | NLD | ITA | HUN | GBR | FRA | ESP | DEU | 1 |
NCT02101918 | Phase II | Aflibercept | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02108782 | Phase II | Dovitinib | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Withdrawn | 0 | |
NCT02230176 | Phase II | Sunitinib lutetium Lu 177 dotatate | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM) | Unknown status | FRA | 0 |
NCT02273752 | Phase II | Everolimus | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | Terminated | USA | 0 |
NCT02315625 | Phase II | Everolimus Sunitinib | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | Terminated | USA | 0 |
NCT02575300 | Phase II | Ibrutinib | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | Completed | USA | 0 |
NCT02687958 | Phase II | Everolimus | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin | Active, not recruiting | ITA | 0 |
NCT02893930 | Phase II | Sapanisertib | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
NCT03043664 | Phase Ib/II | Lanreotide acetate + Pembrolizumab | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET) | Completed | USA | 0 |
NCT03049189 | Phase III | 177Lu-edotreotide Everolimus | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | 1 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03411915 | Phase I | XmAb18087 | A Study of XmAb18087 in Subjects With NET and GIST | Completed | USA | 0 |
NCT03670030 | Phase II | Nab-rapamycin | A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System | Terminated | USA | 0 |
NCT03870399 | Phase II | Tamoxifen | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET) | Completed | USA | BRA | 0 |
NCT03879694 | Phase I | Octreotide + Sargramostim + SurVaxM | Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT03891784 | Phase II | Abemaciclib | Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
NCT03901378 | Phase II | Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | Withdrawn | USA | 0 |
NCT03972488 | Phase III | Octreotide acetate lutetium Lu 177 dotatate + Octreotide acetate | Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
NCT03980925 | Phase II | Carboplatin + Etoposide + Nivolumab | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | Active, not recruiting | ESP | 0 |
NCT04427787 | Phase II | Cabozantinib + Lanreotide acetate | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) | Unknown status | ITA | 0 |
NCT04525638 | Phase II | lutetium Lu 177 dotatate + Nivolumab | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | Unknown status | ESP | 0 |
NCT04919226 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin 177Lu-edotreotide Everolimus Capecitabine + Temozolomide | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE) | Recruiting | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 1 |
NCT05053854 | Phase I | lutetium Lu 177 dotatate + Talazoparib | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET) | Recruiting | AUS | 0 |
NCT05247905 | Phase II | lutetium Lu 177 dotatate Capecitabine + Temozolomide | Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT05249114 | Phase I | Cabozantinib + lutetium Lu 177 dotatate | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
NCT05262556 | Phase I | Ipilimumab + Nivolumab + Thymoquinone | TQ (Thymoquione) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas | Active, not recruiting | USA | 0 |
NCT05364944 | Phase I | Debio 4126 + Lanreotide acetate Debio 4126 + Octreotide acetate | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01) | Active, not recruiting | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | 0 |
NCT05477576 | Phase Ib/II | Everolimus Lanreotide acetate RYZ101 Sunitinib Octreotide acetate | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) | Recruiting | USA | NLD | FRA | ESP | CAN | BRA | BEL | 0 |
NCT05554003 | Phase II | Temozolomide | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study (MeTe) | Recruiting | ITA | 0 |
NCT05568017 | Phase II | Y-90-DOTATOC | Neoadjuvant PRRT With Y-90-DOTATOC in pNET | Unknown status | ITA | 0 |
NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ITA | ISR | FRA | ESP | DEU | AUS | 2 |
NCT05610826 | Phase Ib/II | lutetium Lu 177 dotatate | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | Withdrawn | USA | 0 |
NCT05652686 | Phase I | PT217 | A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Recruiting | USA | 0 |
NCT05687123 | Phase I | lutetium Lu 177 dotatate + Sunitinib | Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors | Recruiting | USA | CAN | 0 |
NCT05701241 | FDA approved | Lanreotide acetate Octreotide acetate | Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA) | Recruiting | NLD | BEL | 0 |
NCT05746208 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05987176 | Phase II | lutetium Lu 177 dotatate | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS) | Recruiting | GBR | 0 |
NCT05988918 | Phase II | CEP-11981 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | Recruiting | USA | 0 |
NCT05997056 | Phase II | Nab-rapamycin | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Recruiting | USA | 0 |
NCT06016855 | FDA approved | lutetium Lu 177 dotatate | Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors | Recruiting | USA | 0 |